Helicobacter pylori
Infection, Pathogenesis & Natural Treatment
A Focus on Sulforaphane as a Complementary Therapeutic Agent
AUTHORS
Andrew Adel
George Nader
Samy Nagy
Academic Year 2025 – 2026
ABSTRACT
Background:
Helicobacter pylori is a Gram-negative, spiral-shaped bacterium responsible for chronic gastric infectioninoverhalftheglobalpopulation.Itistheprimaryetiologicalagentofpepticulcerdisease andarecognizedcarcinogenforgastricadenocarcinoma
Objective:
ThispaperexaminesthepathophysiologyofH.pyloriinfection,reviewscurrentstandardantibioticbased treatment regimens, and investigates the emerging role of sulforaphane a natural isothiocyanatefromBrassicavegetables asacomplementarytherapeuticagent.
Conclusion:
Sulforaphane demonstrates measurable suppression of H. pylori colonization and gastric inflammation in clinical settings. While it cannot yet replace standard antibiotic therapy, it holds significantpotentialasasupportivenaturaladjunct,particularlygivenrisingantibioticresistance.
Keywords: Helicobacter pylori, sulforaphane, broccoli sprouts, peptic ulcer, gastritis, antimicrobial, natural therapy, glucoraphanin
1. INTRODUCTION
Helicobacter pylori (H. pylori) is a Gram-negative, microaerophilic, spiral-shaped bacterium that colonizes the gastric mucosa of approximately 4.4 billion individuals worldwide, making it the most prevalent chronic bacterial infection in the human population. Despite its widespread prevalence, the majority of infected individuals remain asymptomatic throughout their lives. However, a significant subset of patients develops clinically serious complications, including chronic gastritis, peptic ulcer disease,and inasmallerproportion gastricadenocarcinomaormucosa-associatedlymphoidtissue (MALT)lymphoma.
ThebacteriumwasfirstidentifiedbyAustralianphysiciansBarryMarshallandRobinWarrenin1982,a discoverythat fundamentallytransformedthe understanding ofpepticulcerdiseaseandearnedthem the Nobel Prize in Physiology or Medicine in 2005. Prior to this discovery, peptic ulcers were predominantlyattributedtostressanddietaryfactorsratherthanbacterialinfection.
Currentfirst-linetreatmentreliesonantibiotic-basedtripleorquadrupletherapycombinedwithproton pumpinhibitors.However,theglobalriseofantibioticresistance particularlytoclarithromycinand metronidazole has significantly reduced eradication rates. This challenge has stimulated scientific interestincomplementaryandnaturaltherapeuticagents,amongwhichsulforaphanehasemergedasa particularlypromisingcandidate.
2. MICROBIOLOGY AND PATHOGENESIS
2.1
Bacterial Characteristics
H.pyloriisasmall(0.5–1.0µmdiameter,2–4µmlength),spiral-shaped,Gram-negativebacterium.Itis microaerophilic, requiring 5–10% oxygen for optimal growth, and equipped with multiple unipolar flagellathatfacilitatemotilitythroughtheviscousgastricmucuslayer.Acriticalsurvivalmechanismis theproductionofurease,whichhydrolyzesureaintoammoniaandCO₂,locallyraisingpHandcreating aneutralizedmicroenvironmentwithintheacidicstomach.
2.2
Mechanisms of Gastric Injury
Onceestablishedwithinthegastricmucosa,H.pyloriinducesinjurythroughmultiplemechanisms:
• Productionofcytotoxin-associatedgeneA(CagA)protein,whichdisruptsepithelialcell signalingandpromotescarcinogenesis.
• ExpressionofvacuolatingcytotoxinA(VacA),inducingcytoplasmicvacuolationandimpaired immunefunction.
• Releaseoflipopolysaccharides(LPS)andoutermembraneproteinstriggeringchronic inflammation.
• Stimulationofpro-inflammatorycytokinesincludingIL-8,TNF-α,andIL-1β,perpetuating gastricmucosaldamage.
3. EPIDEMIOLOGY AND RISK FACTORS
H. pylori affects an estimated 44% of the global population, with markedly higher prevalence in developing regions. Infection is predominantly acquired in childhood and persists lifelong without treatment.Primarytransmissionroutesinclude:
• Fecal-oraltransmissionviacontaminatedwaterorfoodsupplies.
• Oral-oraltransmissionthroughsharedutensilsorclosepersonalcontact.
• Gastro-oralroutethroughcontactwithvomitusfromaninfectedindividual.
Keydemographicriskfactorsinclude:
• Age:Over50%ofinfectedindividualsindevelopedcountriesareoverage50.
• Ethnicity:HigherprevalenceamongAfricanAmerican,Latino,andEasternEuropeanimmigrant populations.
• Socioeconomicstatus:Crowdedlivingconditionsandlimitedaccesstocleanwaterarestrongly associatedwithhigherpediatricinfectionrates.
4. CLINICAL MANIFESTATIONS AND DISEASE PHENOTYPES
The clinical spectrum of H. pylori infection ranges from asymptomatic carriage to life-threatening malignancy.Diseaseexpressionisshapedbybacterialvirulencefactors,hostgeneticsusceptibility,and environmentalcofactors.Thethreeprincipalphenotypesaresummarizedbelow:
Gastric Cancer
Dyspeptic symptoms; duodenal ulcer
Corpus-predominant Low/absent acid Atrophic gastritis; intestinal metaplasia; cancer
Symptomatic patients most commonly report epigastric burning or discomfort, typically worsening hoursaftereatingoratnight.Additionalsymptomsincludenausea,bloating,earlysatiety,unexplained weightloss,andindigestion.Incasesofactiveulceration,hematemesismayoccur,requiringimmediate medicalintervention.
5. DIAGNOSTIC METHODS
5.1 Non-Invasive Tests
• UreaBreathTest(UBT):Goldstandardfornon-invasivediagnosis.RadiolabeledCO₂inexhaled breathconfirmsureaseactivity.
• StoolAntigenTest(SAT):DetectsH.pyloriantigensinfecalsamples;usedfordiagnosisand post-treatmentverification.
• Serology(BloodTest):DetectsIgGantibodies;limitedutilityforconfirmingactiveinfection sinceantibodiespersistpost-eradication.
5.2 Invasive Tests
• UpperEndoscopy(EGD)withBiopsy:Directvisualizationandtissuesamplingfor histopathologyandculture.
• RapidUreaseTest(RUT):Color-changereactioninbiopsiedtissueconfirmsureaseactivity.
6. STANDARD TREATMENT PROTOCOLS
Recommended treatment is combination pharmacotherapy ('triple' or 'quadruple' therapy) administeredovera10–14daycourse.
6.1 Antibiotic Regimens
1. Amoxicillin beta-lactam;inhibitsbacterialcellwallsynthesis.
2. Clarithromycin macrolide;resistanceratesincreasingglobally.
3. Metronidazole nitroimidazole;resistancealsorising.
4. Tetracycline usedinbismuth-basedquadrupletherapy.
6.2 Proton Pump Inhibitors
5. Omeprazole
6. Pantoprazole
7. Esomeprazole
8. Lansoprazole
⚠ Clinical Concern: Antibiotic Resistance
Global eradication rates with standard triple therapy have declined significantly. Clarithromycin resistance exceeds 15% in many regions; metronidazole resistance exceeds 40% in some populations. This trend underscores the urgent need for alternative or complementary treatment strategies.
Dietarymodificationscansignificantlyreducesymptomseverityandsupporthealing,thoughdietalone cannoteradicatethebacteria.Patientsshouldavoid:
• Spicyfoods aggravatemucosalinflammation.
• Acidicfoods citrusfruitsmayexacerbateacid-relateddiscomfort.
• Fattyandfriedfoods slowgastricemptying.
• Caffeinatedbeverages stimulateacidproduction.
• Alcohol directlyirritatesthegastriclining.
• Ultra-processedfoods additivesmayworsengastricinflammation.
8. SULFORAPHANE AS A NATURAL THERAPEUTIC AGENT
8.1 Chemical Profile and Source
Sulforaphane (C₆H₁₁NOS₂) is a naturally occurring isothiocyanate found abundantly in cruciferous vegetables, most concentrated in broccoli sprouts (Brassica oleracea var. italica). It is generated enzymaticallyfromglucoraphaninbymyrosinaseuponcellulardisruption(e.g.,chewingorcrushing).
8.2 Mechanisms of Antimicrobial Action
• Inhibitionofbacterialureaseactivity reducingtheorganism'sacid-neutralizingcapacity.
• Disruptionofbacterialoutermembraneintegrity promotingbacteriallysis.
• InductionoftheNrf2/AREpathwayinhostcells enhancingantioxidantdefenses.
• SuppressionofNF-κBsignaling reducingpro-inflammatorycytokines(IL-8,TNF-α).
9. CLINICAL EVIDENCE FOR SULFORAPHANE EFFICACY
Multiple human clinical studies have evaluated sulforaphane against H. pylori. The most widely cited protocolinvolvesdailyconsumptionofstandardizedbroccolisproutsasadeliveryvehicle.
9.1 Key Study Findings
Participantsconsuming~70goffreshbroccolisproutsdailyover8weeksdemonstrated:
• StatisticallysignificantreductioninH.pyloribacterialload(measuredbyUBT).
• Measurabledecreaseingastricmucosalinflammationviahistopathologyandserum biomarkers.
• Improvedpatient-reportedgastrointestinalsymptomsduringsupplementation.
Important Limitation:
Sulforaphane's effects appear bacteriostatic rather than bactericidal. Upon cessation of supplementation, H. pylori counts returned to baseline within weeks indicating suppression of proliferationratherthaneradication.Thisfindingsuggestssulforaphane'sgreatestvaluemaybeas anadjunctto,ratherthanareplacementfor,antibiotictherapy.
9.2 Concentrated Formulation Proposal
To achieve higher, more consistent therapeutic concentrations, researchers propose extracting and purifyingsulforaphanefrombroccolisproutsforformulationasastandardizednaturalsupplement.This would allow reproducible dosing, greater bioavailability, and potential integration into structured clinicalprotocols.
10. DISCUSSION
The convergence of increasing antibiotic resistance and growing interest in natural therapeutics positions sulforaphane as a credible area of clinical investigation. Its multifaceted mechanism combiningdirectantimicrobialeffectswithmodulationofhostinflammatorypathways distinguishes itfromsingle-targetpharmaceuticalagents.
Challengesremain:thecurrentevidencebasederivesprimarilyfromsmall-to-mediumtrialswithshort follow-up periods. Larger, multicenter randomized controlled trials are needed to establish optimal dosing,formulationstability,andlong-termsafetyprofiles.Thebacteriostaticnatureofsulforaphane's action suggests its greatest clinical value may lie in combination with standard antibiotic therapy, potentiallyreducingantibioticburdenandassociatedadverseeffects.
11. CONCLUSION
Helicobacter pylori remains one of the most globally significant chronic bacterial infections, with substantialmorbidityfrompepticulcerationandgastricmalignancy.Standarderadicationtherapyfaces growingchallengesfromantimicrobialresistance.
Sulforaphane,derivedfrombroccolisprouts,representsascientificallyvalidatednaturalcompoundwith demonstrable antimicrobial and anti-inflammatory activity. Clinical studies confirm its capacity to reducebacterialcolonizationandgastricinflammationduringsupplementation.Itssafetyprofile,natural
origin, and mechanistic complementarity with existing therapies make it a compelling candidate for furtherclinicaldevelopment.
Future research should prioritize well-designed randomized controlled trials to define sulforaphane's role whether as a standalone bacteriostatic agent, resistance-modifying adjunct, or maintenance therapypreventingre-colonizationaftersuccessfulantibioticeradication.
REFERENCES
1.Marshall,B.J.,&Warren,J.R.(1984).Unidentifiedcurvedbacilliinthestomachofpatientswithgastritisand pepticulceration.TheLancet,323(8390),1311–1315.
2.Hooi,J.K.Y.,etal.(2017).GlobalPrevalenceofHelicobacterpyloriInfection:SystematicReviewandMetaAnalysis.Gastroenterology,153(2),420–429.
3.Fahey,J.W.,etal.(2002).Sulforaphaneinhibitsextracellular,intracellular,andantibiotic-resistantstrainsof Helicobacterpylori.PNAS,99(11),7610–7615.
4.Yanaka,A.,etal.(2009).DietarySulforaphane-RichBroccoliSproutsReduceColonizationandAttenuate GastritisinH.pylori–InfectedMiceandHumans.CancerPreventionResearch,2(4),353–360.
5.WorldHealthOrganization.(2023).HelicobacterpyloriEradicationasaStrategyforGastricCancerPrevention. WHO/HSE/PED/23.1.
6.Malfertheiner,P.,etal.(2022).ManagementofH.pyloriinfection:MaastrichtVI/Florenceconsensusreport. Gut,71(9),1724–1762.
7.Deng,R.,etal.(2021).MechanismsofSulforaphaneinGastroprotection:ASystematicReview.Frontiersin Pharmacology,12,689429.
8.ClevelandClinic.(2023).Helicobacterpylori(H.pylori)Infection.my.clevelandclinic.org.
9.NationalCancerInstitute.(2022).H.pyloriandCancer.NationalInstitutesofHealth.
10.Zhang,L.,etal.(2020).Glucoraphaninandsulforaphanebioavailabilityfromdietarysupplements.Molecular Nutrition&FoodResearch,64(12),e2000342.